Agilent Technologies has completed its acquisition of BIOVECTRA, a contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.

All closing conditions are completed, including receipt of regulatory approvals. BIOVECTRA is now part of Agilent’s Diagnostics and Genomics Group.

“We are delighted to officially welcome the BIOVECTRA team to Agilent. This acquisition demonstrates our commitment to providing customers the most advanced capabilities to accelerate their therapeutic programs, including best-in-class cGMP pharmaceutical manufacturing,” said Padraig McDonnell, President and CEO, Agilent.

With the addition of BIOVECTRA, Agilent will expand its portfolio of CDMO services, add rapidly growing modalities, and bring world-class capabilities to support gene editing.

Agilent expects the transaction will be USD 0.05 dilutive to non-GAAP earnings per share (EPS) in the first full year after closing and deliver a double-digit return on invested capital (ROIC) by year five. Agilent funded the transaction using a mix of cash on hand and debt financing.

Agilent Technologies delivers insights and innovation that help their customers bring great science to life.

Agilent’s full range of solutions includes instruments, software, services, and expertise that provides trusted answers to its customers' most challenging questions. The company generated revenue of USD 6.83 billion in fiscal 2023 and employed approximately 18,000 people worldwide.